Cargando…

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

mRNA represents a promising new vaccine technology platform with high flexibility in regard to development and production. Here, we demonstrate that vaccines based on sequence optimized, chemically unmodified mRNA formulated in optimized lipid nanoparticles (LNPs) are highly immunogenic and well tol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lutz, Johannes, Lazzaro, Sandra, Habbeddine, Mohamed, Schmidt, Kim Ellen, Baumhof, Patrick, Mui, Barbara L., Tam, Ying K., Madden, Thomas D., Hope, Michael J., Heidenreich, Regina, Fotin-Mleczek, Mariola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648897/ https://www.ncbi.nlm.nih.gov/pubmed/29263884 http://dx.doi.org/10.1038/s41541-017-0032-6

Ejemplares similares

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
por: Thess, Andreas, et al.
Publicado: (2015)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines
por: Kallen, Karl-Josef, et al.
Publicado: (2013)

mRNA mediates passive vaccination against infectious agents, toxins, and tumors
por: Thran, Moritz, et al.
Publicado: (2017)

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors
por: Fotin-Mleczek, Mariola, et al.
Publicado: (2014)

RNAdjuvant(®), a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile
por: Heidenreich, Regina, et al.
Publicado: (2015)

Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits
por: Mucker, Eric M., et al.
Publicado: (2022)

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021)

Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
por: Tombácz, István, et al.
Publicado: (2021)

SV-AUC as a stability-indicating method for the characterization of mRNA-LNPs
por: Thaller, Anian, et al.
Publicado: (2023)

siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
por: Kalita, Tutu, et al.
Publicado: (2022)

Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity
por: Lutz, Johannes, et al.
Publicado: (2022)

Development of an Alcohol Dilution–Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability
por: Shirane, Daiki, et al.
Publicado: (2023)

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
por: Sebastian, Martin, et al.
Publicado: (2014)

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response
por: Edwards, Darin K., et al.
Publicado: (2017)

Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size
por: Di, Jiaxing, et al.
Publicado: (2022)

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
por: Golubovskaya, Vita, et al.
Publicado: (2023)

Allele-Specific Isothermal Amplification Method Using Unmodified Self-Stabilizing Competitive Primers
por: Malpartida-Cardenas, Kenny, et al.
Publicado: (2018)

Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine
por: Li, Mingyuan, et al.
Publicado: (2023)

PHYSICAL MORBIDITY AND UNMODIFIED ECT
por: Gangadhar, B. N., et al.
Publicado: (1994)

MODIFIED VERSUS UNMODIFIED ECT
por: Shukla, G.D.
Publicado: (2000)

Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution
por: Münter, Rasmus, et al.
Publicado: (2023)

A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
por: Koch, Sven D, et al.
Publicado: (2014)

Effect of Cholesterol Content of Lipid Composition in mRNA-LNPs on the Protein Expression in the Injected Site and Liver After Local Administration in Mice
por: Kawaguchi, Maho, et al.
Publicado: (2023)

UNMODIFIED ECT: A NOTE OF CAUTION
por: Andrade, Chittaranjan
Publicado: (1995)

The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta
por: Keikha, Reza, et al.
Publicado: (2021)

Position statement and guidelines on unmodified electroconvulsive therapy
por: Andrade, Chittaranjan, et al.
Publicado: (2012)

Drivers of macroinvertebrate community structure in unmodified streams
por: Tonkin, Jonathan D.
Publicado: (2014)

Unmodified Clay Nanosheets at the Air–Water Interface
por: Michels-Brito, Paulo H., et al.
Publicado: (2020)

DoE-derived continuous and robust process for manufacturing of pharmaceutical-grade wide-range LNPs for RNA-vaccine/drug delivery
por: Nag, Kakon, et al.
Publicado: (2022)

Established Liposome-Coated IMB16-4 Polymeric Nanoparticles (LNPs) for Increasing Cellular Uptake and Anti-Fibrotic Effects In Vitro
por: Niu, Xia, et al.
Publicado: (2022)

Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models
por: Wei, Tuo, et al.
Publicado: (2023)

In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice
por: Han, Jeong Pil, et al.
Publicado: (2023)

MODIFIED VERSUS UNMODIFIED ECT : IS THERE A PARADIGM SHIFT?
por: Duggal, Harpreet S., et al.
Publicado: (2001)

PHYSICAL MORBIDITY WITH UNMODIFIED ECT - A DECADE OF EXPERIENCE
por: Tharyan, Prathap, et al.
Publicado: (1993)

Anesthesiological training and certification for psychiatrists practising unmodified ECT
por: Andrade, Chittaranjan
Publicado: (2013)

Single pot organic solvent-free thermocycling technology for siRNA-ionizable LNPs: a proof-of-concept approach for alternative to microfluidics
por: De, Anindita, et al.
Publicado: (2022)

ABE8e Corrects Pax6-Aniridic Variant in Humanized Mouse ESCs and via LNPs in Ex Vivo Cortical Neurons
por: Adair, Bethany A., et al.
Publicado: (2023)

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
por: Hong, Henoch S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g5eoac2p80fvp5mnadjr2hpbee